SWK Holdings Corp
NASDAQ:SWKH
SWK Holdings Corp
Net Income (Common)
SWK Holdings Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SWK Holdings Corp
NASDAQ:SWKH
|
Net Income (Common)
$10.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-3%
|
|
|
LM Funding America Inc
NASDAQ:LMFA
|
Net Income (Common)
-$11.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
A-Mark Precious Metals Inc
NASDAQ:AMRK
|
Net Income (Common)
$51.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
103%
|
CAGR 10-Years
23%
|
|
|
FlexShopper Inc
NASDAQ:FPAY
|
Net Income (Common)
-$3.5m
|
CAGR 3-Years
-148%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
California First Leasing Corp
OTC:CFNB
|
Net Income (Common)
$33.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
S
|
Standard Premium Finance Holdings Inc
OTC:SPFX
|
Net Income (Common)
$416.2k
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SWK Holdings Corp
Glance View
SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.
See Also
What is SWK Holdings Corp's Net Income (Common)?
Net Income (Common)
10.6m
USD
Based on the financial report for Sep 30, 2024, SWK Holdings Corp's Net Income (Common) amounts to 10.6m USD.
What is SWK Holdings Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
Over the last year, the Net Income (Common) growth was -33%. The average annual Net Income (Common) growth rates for SWK Holdings Corp have been -24% over the past three years , -12% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet